A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event
Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease. The main purpose of the study is to investigate how lepodisiran, compared to a placebo, affects the amount and type of plaque in the heart's vessels using an imaging technology known as Coronary Computed Tomography Angiography (CCTA) in adults who have high levels of Lp(a).
Participation will last about 120 weeks.
Inclusion Criteria:
Exclusion Criteria:
LillyTrials@Lilly.com317-615-4559
clinical_inquiry_hub@lilly.com
La Jolla, California 92037-7410, United States
858-246-2510
Torrance, California 90502, United States
Fort Lauderdale, Florida 33312, United States
Winter Park, Florida 32789, United States
Birtinya, 4575, Australia
Sheffield, S5 7AU, United Kingdom
818-678-4900
424-201-3000
954-963-7100
904-730-0101
786-502-4303
407-740-8078
208-398-4306
617-726-1843
947-254-1920
702-750-000
717-851-2441
801-507-4707
703-766-5920
425-869-6828
61738765688
61894006111
+61 2 4963 2323
(03) 8793 3800
420 606 417 244
00420 734 395 787
36 70 450 8040
3614586840
0036209530430
0341463745
0715828485
0773205603
34 628 544 729
93 248 30 39
932850000
34957010947
663873243
0034 913 30 30 00
34955034939
0034 955 01 20 00
0121 592 2050
07452948414
+44 114 2266159
01438 314333
01918205151